Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[4]. - The net profit attributable to shareholders for the same period was 300 million RMB, up 20% compared to the previous year[4]. - The company's operating revenue for the first half of 2022 reached RMB 776,881,166.02, representing a 45.33% increase compared to RMB 534,556,471.63 in the same period last year[15]. - The net profit attributable to shareholders for the first half of 2022 was RMB 371,119,594.26, a significant increase of 141.40% from RMB 153,734,926.32 in the previous year[15]. - The net cash flow from operating activities for the first half of 2022 was RMB 545,493,427.60, which is a 169.43% increase from RMB 202,465,705.85 in the previous year[15]. - Future guidance indicates a revenue growth target of 20% for the full year 2022[4]. - The total order amount on hand reached over 4.1 billion RMB, providing a solid foundation for future performance[57]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[4]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[4]. - The company is focusing on expanding its market presence in the CRO and experimental model sectors, driven by increasing domestic and international demand[25]. Research and Development - The company has allocated 200 million RMB for R&D in 2022, a 30% increase from the previous year[4]. - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials by Q4 2022[4]. - The company is developing a leading genetic resource and gene engineering technology platform for creating animal disease models for new drug development[34]. - The company has established a comprehensive drug screening platform for both in vitro and in vivo evaluations, improving the efficiency of drug development[46]. Financial Position - The total assets of the company at the end of the reporting period amounted to RMB 10,646,728,994.36, marking a 24.71% increase from RMB 8,537,077,111.40 at the end of the previous year[15]. - The net assets attributable to shareholders at the end of the reporting period were RMB 7,398,296,481.53, showing a 3.67% increase from RMB 7,136,214,378.04 at the end of the previous year[15]. - The company's cash and cash equivalents at the end of the period amounted to ¥3,800,990,974.43, representing 35.69% of total assets, a decrease of 8.50% compared to the previous year[62]. - The company reported a substantial increase in productive biological assets, which reached ¥777,775,918.46, a 949.42% increase due to acquisitions and fair value adjustments[63]. Risk Management - The management highlighted potential risks related to regulatory changes and market competition[4]. - The company faces risks related to international economic fluctuations, which may negatively impact the pharmaceutical industry and drug innovation investments due to the ongoing COVID-19 pandemic[73]. Environmental Commitment - The company emphasized its commitment to environmental protection and sustainable development, implementing a comprehensive environmental management system[83]. - The company plans to continue investing in environmental improvements to ensure compliance with pollution discharge standards[83]. - The company ensures compliance with environmental standards, including wastewater discharge limits and air pollutant emission standards, through regular third-party inspections and treatment processes[88]. Shareholder Information - The company granted 675,400 restricted A shares to 505 incentive recipients as part of its equity incentive plan approved on January 28, 2022[80]. - The company distributed cash dividends of 0.36 yuan per share and increased capital reserves by 0.4 shares per share, resulting in a total share capital of 534,191,429 shares[103]. - The largest shareholder, Feng Yuxia, held 85,286,037 shares, representing 22.35% of the total shares[105]. Compliance and Governance - The company has committed to not engaging in any competitive business activities with its controlling shareholders and related parties, ensuring no conflicts of interest[91]. - There were no non-operational fund occupations or guarantee violations reported during the reporting period[96]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[141].

2022 年第一季度报告 单位：元币种：人民币 证券代码：603127 证券简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 270,975,486.87 ...

Financial Performance - The company's operating revenue for Q1 2022 was RMB 270,975,486.87, representing a year-on-year increase of 34.82%[3] - Net profit attributable to shareholders for the same period was RMB 125,347,354.57, reflecting a growth of 34.27% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 66.65% year-on-year, amounting to RMB 132,381,980.64[3] - Basic earnings per share for the quarter were RMB 0.33, up 17.86% year-on-year[3] - The company reported a significant increase in cash inflow from investment activities compared to the previous year, indicating a positive trend in investment returns[27] Cash Flow - The net cash flow from operating activities reached RMB 74,906,349.49, a significant increase of 117.23% compared to the previous year[3] - Cash inflow from investment activities totaled approximately $334.48 million, with a net cash inflow from investment activities of about $72.50 million[27] - The cash flow from operating activities generated a net amount of CNY 74,906,349.49 in Q1 2022, compared to CNY 34,482,082.76 in Q1 2021, indicating a growth of 117.5%[26] - The cash flow from investment activities showed a substantial improvement compared to the previous year's negative cash flow of approximately $66.69 million[27] - The company’s cash position remains strong, with a significant balance of cash and cash equivalents at the end of the reporting period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,957,151,364.84, an increase of 4.92% from the end of the previous year[4] - Total current assets increased to CNY 6,186,990,976.77 as of March 31, 2022, compared to CNY 5,814,484,316.60 at the end of 2021, representing a growth of 6.4%[14] - Non-current assets totaled CNY 2,770,160,388.07 as of March 31, 2022, slightly up from CNY 2,722,592,794.80 at the end of 2021[15] - Total liabilities increased to CNY 1,685,280,811.53 as of March 31, 2022, compared to CNY 1,392,640,954.56 at the end of 2021, indicating a rise of 20.9%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,729[10] - The top shareholder, Feng Yuxia, holds 89,702,855 shares, accounting for 23.51% of total shares[10] Business Growth - New orders signed exceeded 1 billion RMB, representing a year-on-year growth of over 65%[12] - The total amount of orders on hand reached over 3.6 billion RMB at the end of the reporting period[12] - Operating revenue increased by 34.82% due to business growth[9] - Net profit attributable to shareholders increased by 34.27% driven by business expansion[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 66.65% as a result of business growth[9] Research and Development - Research and development expenses increased to CNY 12,289,064.34 in Q1 2022, compared to CNY 9,878,808.23 in Q1 2021, reflecting a growth of 24.3%[19] - Future outlook includes continued investment in R&D to drive innovation and market expansion strategies[19] Other Financial Metrics - The company reported a fair value loss of RMB 14,472,000 related to trading financial assets, impacting net profit[5] - The unrealized gain from biological assets was RMB 34,494,000, contributing positively to net profit[6] - The company received government subsidies amounting to RMB 2,580,000 during the reporting period[5] - The weighted average return on net assets decreased by 1.34 percentage points due to the full weighting of net assets raised from the Hong Kong stock issuance[9] - The company's total profit for Q1 2022 was CNY 139,756,935.47, up from CNY 104,035,964.94 in Q1 2021, reflecting an increase of 34.4%[20]

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[6]. - The company achieved a net profit of RMB 300 million, which is an increase of 30% compared to the previous year[6]. - Total revenue for 2021 reached RMB 1,516,680,000, a 40.9% increase from RMB 1,075,905,000 in 2020[14]. - Gross profit for 2021 was RMB 735,678,000, resulting in a gross margin of 48.51%[14]. - Net profit attributable to equity shareholders for 2021 was RMB 557,460,000, up from RMB 312,950,000 in 2020, reflecting an increase of 78.5%[14]. - Basic earnings per share for 2021 were RMB 1.51, compared to RMB 0.99 in 2020, representing a 52.5% increase[14]. - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[6]. - In 2021, the company achieved a revenue growth of approximately 41% year-on-year, with net profit attributable to equity shareholders increasing by about 78%[16]. - The company reported a profit distribution plan for the year ending December 31, 2021, proposing a final dividend of RMB 0.36 per share, up from RMB 0.35 in 2020[73]. - The total amount of the proposed final dividend is approximately RMB 137,248,000, compared to RMB 94,850,000 in 2020[73]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Europe and North America, targeting a 20% increase in international revenue by 2023[6]. - The company plans to continue expanding its market presence and investing in new product development[12]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to upgrade facilities and expand services in the North American pharmaceutical market[48]. - The company is focusing on strategic partnerships with leading pharmaceutical companies to enhance its service offerings[6]. - The company plans to invest in expanding its clinical trial services and strengthen its scientific and regulatory teams to support clinical trial operations[48]. Research and Development - The company is investing RMB 200 million in R&D for new drug development technologies, aiming to launch two new products by the end of 2022[6]. - Research and development efforts are focused on innovative drug discovery and enhancing drug metabolism studies[11]. - The company has established a comprehensive platform for non-clinical evaluation, focusing on innovative drug research and evaluation capabilities across various new technologies and targets[19]. - The company successfully created gene-edited cell lines and animal models for rare disease drug development, enhancing its innovative drug research capabilities[22]. Operational Efficiency - JOINN Laboratories is implementing new operational strategies to improve efficiency, aiming for a 10% reduction in operational costs by 2023[6]. - The company upgraded its laboratory information management system (LIMS) and introduced new document management and employee training systems to enhance operational efficiency[19]. - The company expanded its workforce to over 2,100 professionals by December 31, 2021, enhancing the capabilities of its non-clinical research service team[17]. Acquisitions and Partnerships - JOINN Laboratories has completed the acquisition of Biomedical Research Models, Inc., enhancing its capabilities in preclinical research[6]. - The company is exploring potential mergers and acquisitions to strengthen its market position and capabilities[12]. - The company aims to selectively pursue acquisitions of businesses and assets that complement its growth strategy, particularly in non-clinical research and drug discovery services[52]. Financial Position and Assets - Total assets as of December 31, 2021, amounted to RMB 8,537,077,000, significantly higher than RMB 2,172,902,000 in 2017[15]. - Total liabilities for 2021 were RMB 1,392,641,000, compared to RMB 951,093,000 in 2020[15]. - Net assets for 2021 stood at RMB 7,144,436,000, an increase from RMB 1,221,809,000 in 2017[15]. - Cash and cash equivalents as of December 31, 2021, were RMB 41,541 million, an increase of 1,245.7% from RMB 3,087 million as of December 31, 2020[43]. Risks and Challenges - The company faces regulatory compliance risks due to the need to adhere to multiple laws and regulations across different countries, which could adversely affect its reputation and financial performance[53]. - Talent recruitment risks are heightened as the company expands, necessitating the cultivation and introduction of skilled personnel to meet current and future business needs[54]. - Market competition risks are increasing as competitors expand capacity and facilities, necessitating the company to maintain its core competitive advantages[55]. - The ongoing COVID-19 pandemic poses challenges to daily operations, and future developments in the pandemic could impact business operations depending on national policies[59]. Corporate Governance - The board consists of 10 members, with executive directors having service contracts established in February 2021 for an initial term of three years[83]. - The company has established a framework for maintaining shareholder interests and enhancing corporate value through effective governance practices[152]. - The board of directors held seven meetings during the reporting period, exceeding the minimum requirement of four meetings per year[175]. - The company has adopted a board nomination policy outlining criteria for selecting candidates for appointment or reappointment[166]. Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations[195]. - Shareholders holding more than 3% of the company's shares can propose temporary motions at least 10 days before the annual general meeting[193]. - The company has established a policy to maintain communication with shareholders, ensuring timely responses to shareholder concerns and suggestions[195]. Employee and Labor Relations - The company has established a union in China to represent employees and ensure compliance with labor laws and regulations[138]. - The employer matches employee contributions to the 401(k) plan up to 4% of eligible wages, providing a safety net for retirement savings[141]. Environmental and Social Responsibility - The company has established detailed internal rules for environmental protection, with no additional costs incurred for compliance as of December 31, 2021[74]. - The company emphasizes compliance with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[138]. - The company made donations amounting to RMB 1.2 million during the reporting period[151].

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.52 billion, representing a 40.97% increase compared to ¥1.08 billion in 2020[17]. - The net profit attributable to shareholders for 2021 was approximately ¥557.46 million, a 76.96% increase from ¥315.01 million in 2020[17]. - The cash flow generated from operating activities in 2021 was approximately ¥685.66 million, up 60.06% from ¥428.39 million in 2020[17]. - The total assets at the end of 2021 were approximately ¥8.54 billion, a 305.02% increase from ¥2.11 billion at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥7.14 billion, reflecting a 482.60% increase from ¥1.22 billion at the end of 2020[17]. - The basic earnings per share for 2021 were ¥1.51, a 51.00% increase compared to ¥1.00 in 2020[18]. - The diluted earnings per share for 2021 were ¥1.50, representing a 51.52% increase from ¥0.99 in 2020[18]. - The weighted average return on equity for 2021 was 9.42%, down 21.36% from 30.78% in 2020[18]. - The company achieved a revenue of CNY 1,516.68 million in 2021, representing a year-on-year growth of 40.97%[64]. - The net profit attributable to shareholders was CNY 557.82 million, reflecting a year-on-year increase of 77.08%[64]. Investments and Capital Structure - The company plans to distribute a cash dividend of 3.6 CNY per 10 shares (including tax) and to increase capital by converting 4 shares for every 10 shares held[3]. - The company made strategic investments in Changchun Baike Biotechnology Co., Ltd. and Beijing Zhaoyan Biotechnology Co., Ltd., with total investments of ¥4,362 million and ¥5,000 million respectively, enhancing business cooperation and market competitiveness[78]. - The fair value of financial products increased to ¥605,533,634.18, up from ¥238,902,999.99 in the previous period, reflecting a strong growth in investment performance[80]. - The company reported a total of 1,135,000,000 RMB in entrusted financial management, with an outstanding balance of 600,000,000 RMB[160]. - The total number of shares increased from 227,454,729 to 381,246,492 shares due to various stock options and capital increases[162][164][166]. Operational Developments - The company expanded its workforce to over 2,100 professionals by the end of 2021, enhancing its service capabilities[24]. - A new 7,500 square meter breeding facility was completed and put into use by the end of 2021, supporting increased operational capacity[25]. - The company is constructing an additional 20,000 square meters of facilities to meet growing experimental demands, expected to be operational in the second half of 2022[25]. - Approximately 6,000 square meters of new experimental facilities were renovated in California to alleviate capacity constraints at the overseas subsidiary BIOMERE[26]. - The company has established a competitive compensation scheme, including stock incentives, to enhance employee motivation and retention[24]. Market Position and Strategy - The company achieved a total order amount of approximately RMB 29 billion in 2021, providing a solid foundation for future performance[33]. - The company signed orders exceeding RMB 28 billion in 2021, with domestic orders amounting to over RMB 25.5 billion, representing a year-on-year growth of approximately 65%[34]. - The overseas subsidiary BIOMERE secured orders of about RMB 2.8 billion in 2021, reflecting a year-on-year increase of approximately 75%[36]. - The company is focused on expanding its market presence through strategic partnerships and investments in biotechnology, aiming for long-term growth[109]. - The company plans to expand its market presence and is focusing on new product development and technological advancements[107]. Governance and Compliance - The financial report has been audited by KPMG Huazhen, which issued a standard unqualified opinion[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company maintained independent operations and governance, ensuring no interference from controlling shareholders during the reporting period[100]. - The company has implemented measures to maintain independence in assets, personnel, and operations from controlling shareholders[101]. - The company has not faced any penalties from securities regulatory authorities in the past three years[114]. Research and Development - The company is committed to adhering to Good Laboratory Practice (GLP) standards in its research activities[7]. - The company has established a complete cell testing system in 2021, addressing the quality inspection needs for cell lines and cell banks, which is expected to become a new growth point[31]. - The company’s clinical sample testing segment has expanded to include a wide range of innovative drugs, significantly reducing method transfer time for clients[29]. - The company has developed specialized evaluation techniques for various innovative biopharmaceuticals, including gene drugs and complex antibody drugs, creating new competitive advantages[55]. - The company is investing in research and development to innovate new products, aiming to launch at least three new products in the next fiscal year[107]. Environmental Responsibility - The company emphasized the importance of environmental protection and sustainable development in its operational policies[140]. - The company has established a comprehensive environmental management system and conducts regular checks on its environmental performance[140]. - The company has committed to improving its wastewater treatment facilities to meet higher standards[143]. - The company implemented measures to reduce carbon emissions, including the use of energy-efficient LED lights and electric vehicles[144]. - The company conducted regular third-party inspections to ensure compliance with environmental discharge standards[143]. Risks and Challenges - The company faces risks from fluctuating international economic conditions and potential reductions in pharmaceutical innovation investments due to the ongoing COVID-19 pandemic[96]. - The company acknowledges the challenges posed by the COVID-19 pandemic and its potential impact on business operations, despite current control measures[98]. - The company is committed to maintaining its core competitive advantages amid increasing market competition in the non-clinical CRO industry[97]. - The company is focused on developing new technical methods to adapt to industry trends and maintain its leading position in the market[98].

Financial Performance - Q3 2021 revenue reached ¥322,247,927.52, an increase of 37.62% year-over-year[2] - Net profit attributable to shareholders was ¥94,271,234.99, up 76.76% compared to the same period last year[2] - Net profit excluding non-recurring gains and losses for the period was ¥87,962,581.12, reflecting a 94.72% increase year-over-year[2] - Basic earnings per share for Q3 2021 was ¥0.36, up 111.76% from the previous year[3] - Total operating revenue for the first three quarters of 2021 reached ¥856,804,399.15, a 35.7% increase from ¥631,513,285.48 in the same period of 2020[15] - Net profit for the third quarter of 2021 was ¥247,009,521.78, compared to ¥142,479,212.65 in the same quarter of 2020, representing a 73.2% increase[17] - The net profit attributable to shareholders of the parent company for the third quarter of 2021 was ¥248,006,161.31, up from ¥143,556,153.79 in the previous year[19] - Basic earnings per share for the third quarter of 2021 were ¥0.95, compared to ¥0.45 in the same quarter of 2020[19] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period was ¥463,447,574.19, showing a 106.82% increase[3] - The company reported a significant increase in cash flow due to higher sales collections resulting from business growth[7] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 463,447,574.19, a significant increase of 106.7% compared to CNY 224,084,428.91 in the same period of 2020[20] - Total cash inflow from investment activities was CNY 404,057,385.13, up from CNY 331,436,170.51 in the previous year, while cash outflow for investment activities surged to CNY 2,290,934,619.51 from CNY 508,987,148.73[21] - The cash flow from investment activities showed a net outflow of CNY 1,886,877,234.38, compared to a net outflow of CNY 177,550,978.22 in the previous year, indicating increased investment activities[21] - The company’s cash inflow from financing activities was primarily driven by CNY 5,407,415,864.64 received from investments, a significant increase from CNY 32,872,124.88 in the previous year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,201,780,654.41, a 289.11% increase from the previous year[3] - The total assets of the company as of September 30, 2021, amount to 8,201,780,654.41 RMB, compared to 2,107,821,636.06 RMB at the end of 2020[13] - The total liabilities of the company as of September 30, 2021, are 1,237,063,156.75 RMB, compared to 760,042,162.51 RMB at the end of 2020[13] - Total liabilities as of the end of the third quarter of 2021 amounted to ¥1,388,193,843.40, significantly higher than ¥883,657,479.78 at the end of the third quarter of 2020[17] - Total current assets as of the end of the reporting period were CNY 1,182,910,934.76, slightly down from CNY 1,182,686,692.14 at the beginning of the year[23] - Total liabilities decreased to $883,657,479.78 from $951,093,100.06, representing a reduction of about 7%[24] - Non-current liabilities decreased significantly from $176,785,397.88 to $123,615,317.27, a drop of around 30%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,231[8] - The largest shareholder, Feng Yuxia, holds 89,702,855 shares, representing 23.57% of the total shares[9] - Total equity attributable to shareholders of the parent company reached ¥6,815,318,386.55, compared to ¥1,224,899,092.29 in the previous year[17] Business Growth and Orders - The increase in revenue and net profit was primarily driven by business growth and interest income from raised funds[6] - The company has secured over 3 billion RMB in orders as of the end of the reporting period, reflecting a year-on-year increase of over 70% in new orders[10] Research and Development - Research and development expenses for the third quarter of 2021 were ¥35,019,894.79, a decrease from ¥48,885,489.44 in the same period of 2020[17] Accounting and Financial Reporting - The company has implemented revised accounting standards for leases effective January 1, 2021, impacting financial reporting[26]

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 25%[1]. - The net profit attributable to shareholders was 300 million RMB, up 30% compared to the same period last year[1]. - The company's operating revenue for the first half of the year reached ¥534,556,471.63, representing a 34.53% increase compared to ¥397,354,998.31 in the same period last year[14]. - The net profit attributable to shareholders was ¥153,734,926.32, a significant increase of 70.39% from ¥90,223,461.98 in the previous year[14]. - The net cash flow from operating activities was ¥202,465,705.85, up 31.18% from ¥154,344,394.21 year-on-year[14]. - The total assets of the company increased to ¥7,869,165,124.10, reflecting a 273.33% growth compared to ¥2,107,821,636.06 at the end of the previous year[14]. - The net assets attributable to shareholders surged to ¥6,610,662,672.42, marking a 439.69% increase from ¥1,224,899,092.29 at the end of last year[14]. - Basic earnings per share rose to ¥0.60, a 50.00% increase from ¥0.40 in the same period last year[15]. - The diluted earnings per share increased to ¥0.59, up 47.50% from ¥0.40 year-on-year[15]. - The company reported a weighted average return on equity of 3.17%, down 6.96 percentage points from 10.13% in the previous year[15]. Market Expansion and Client Growth - The company expanded its client base by 20%, reaching a total of 200 clients in the first half of 2021[1]. - The company aims to enter two new international markets by the end of 2022, focusing on Europe and North America[1]. - The company’s orders in the first half of 2021 reached approximately RMB 400 million, a year-on-year increase of over 150%[51]. - The overseas subsidiary BIOMERE secured orders of approximately USD 21.5 million, reflecting a year-on-year growth of over 60%[57]. - The company’s domestic orders from overseas clients reached approximately RMB 73 million, a year-on-year increase of over 80%[57]. Research and Development - The number of new drug development projects increased by 15%, with a total of 50 active projects as of June 30, 2021[1]. - The company plans to invest 200 million RMB in R&D for new technologies and products in the next fiscal year[1]. - The company is enhancing its service capabilities and applying new technologies, particularly in the evaluation of innovative drugs, which supports future business expansion[27]. - The company is focusing on developing a leading, efficient, and stable genetic resource and gene engineering technology platform for experimental animals, particularly for new drug development[25]. - The company has established a unique golden industrial chain for preclinical research services, clinical trials, and related services, ensuring high-quality service for clients[18]. Operational Efficiency and Compliance - The company ensures compliance with regulatory requirements and quality management standards in all its services, thereby reducing the risk and increasing the efficiency of drug development for clients[22]. - The company has established a strict procurement process, ensuring effective control over procurement applications, approvals, inquiries, supplier selection, and payments[25]. - The company has implemented a laboratory information management system (LIMS) to improve work efficiency and ensure compliance with GLP regulations, significantly increasing data reliability and integrity[40]. - The company has optimized its organizational structure and compensation system to enhance employee engagement and improve service efficiency[48]. Financial Position and Assets - The company's total assets increased to CNY 115,943.39 million as of June 30, 2021, compared to CNY 79,488.33 million in the same period of 2020, representing a growth of 46.0%[69]. - The total liabilities increased to approximately ¥1.10 billion from ¥760.04 million, reflecting a growth of about 45%[107]. - The company's long-term equity investments increased to approximately ¥102.44 million from ¥64.44 million, showing a growth of about 59%[107]. - The total current assets as of June 30, 2021, amounted to approximately ¥5.37 billion, a significant increase from ¥1.18 billion as of December 31, 2020, reflecting a growth of about 354%[106]. - Cash and cash equivalents increased to approximately ¥4.20 billion from ¥308.69 million, representing a growth of over 1,260%[106]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which may impact future performance[1]. - Intense market competition in the preclinical CRO industry poses risks, with competitors expanding capacity and facilities, potentially impacting profitability if the company fails to maintain its competitive edge[72]. - The company faces talent recruitment risks due to the urgent need for management, technical, and marketing personnel as business scales and expands[71]. - The COVID-19 pandemic has posed operational challenges, although its overall impact on production has been limited; future developments remain uncertain[76]. Environmental and Social Responsibility - Environmental management practices are in place, with a focus on pollution prevention and sustainable development, including regular third-party inspections of emissions[84]. - The company has implemented measures to reduce carbon emissions, including the use of energy-efficient LED lighting and electric vehicles[89]. - The company has established a wastewater treatment facility that meets the standards for discharge into public systems[88]. - The company has engaged third-party testing to ensure compliance with environmental discharge standards[88]. Shareholder and Corporate Governance - The company reported a total share count of 270,820,329 after the issuance of 43,365,600 new shares, representing a 19.1% increase in total shares[96]. - The company has committed to avoiding any competition with its controlling shareholders and related parties, ensuring compliance with competitive regulations[90]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[80]. - The company has not reported any violations or penalties related to its directors, supervisors, or controlling shareholders[94].

Financial Performance - Net profit attributable to shareholders was RMB 93.36 million, up 388.07% year-on-year[4] - Operating revenue for the period was RMB 200.99 million, representing a growth of 29.91% compared to the same period last year[4] - Basic earnings per share rose to RMB 0.39, a 333.33% increase from RMB 0.09 in the previous year[4] - Excluding the impact of foreign exchange gains, net profit growth rate was 85.44%[4] - The company reported a total comprehensive income of ¥62,388,926.44 for Q1 2021, compared to ¥22,630,107.43 in Q1 2020[23] - The company's net profit for Q1 2021 was CNY 56,060,823.09, a significant increase compared to CNY 934,455.09 in Q1 2020, reflecting a growth of approximately 5,900%[25] - Total revenue from operating activities reached CNY 334,525,902.11, up from CNY 232,670,305.50 in the same period last year, indicating a growth of about 43.8%[27] Assets and Liabilities - Total assets reached RMB 7.63 billion, an increase of 262.17% compared to the end of the previous year[4] - Total liabilities increased to ¥1,037,666,885.26, up from ¥883,657,479.78, representing a growth of approximately 17.5% year-over-year[16] - Current liabilities totaled ¥875,120,280.13, compared to ¥760,042,162.51, indicating an increase of about 15.1%[16] - Non-current liabilities rose to ¥162,546,605.13 from ¥123,615,317.27, reflecting a growth of approximately 31.5%[16] - Total equity attributable to shareholders reached ¥6,597,313,422.62, significantly up from ¥1,224,899,092.29, marking an increase of around 438.5%[17] - Total assets of the company reached ¥7,633,988,121.93, a substantial increase from ¥2,107,821,636.06, reflecting overall growth in the company's financial position[15] - Total liabilities amounted to ¥883,657,479.78, a decrease of ¥67,435,620.28 compared to the previous period[33] Cash Flow - The company reported a net cash flow from operating activities of RMB 34.48 million, a slight increase of 0.49% year-on-year[4] - Cash and cash equivalents increased significantly to ¥5,657,723,895.31 from ¥308,689,959.55, a change of 1732.82% due to funds raised from the Hong Kong stock market[9] - The net cash flow from financing activities was ¥5,312,443,354.88, a dramatic increase of 331480.4% compared to ¥1,602,158.28 in the previous period, mainly due to funds raised from the Hong Kong stock market[12] - Cash inflow from operating activities totaled CNY 127,310,706.37, a significant increase of 86% compared to CNY 68,375,500.49 in Q1 2020[30] - The net increase in cash and cash equivalents was CNY 5,365,357,040.52, compared to a decrease of CNY 6,288,742.53 in the previous year[31] Shareholder Information - The number of shareholders reached 21,198 by the end of the reporting period[7] - The top shareholder, Feng Yuxia, holds 23.66% of the shares, totaling 64,073,468 shares[8] Other Financial Metrics - The weighted average return on equity increased by 0.80 percentage points to 3.08%[4] - The company completed its H-share listing on February 26, 2021, raising HKD 6.373 billion, with a foreign exchange gain impacting net profit by RMB 57.89 million[4] - The company incurred financial expenses of CNY 67,971,575.70, compared to CNY 45,241.27 in the previous year, indicating a rise in financial costs[25] - Research and development expenses for Q1 2021 were ¥9,878,808.23, a decrease of 16% from ¥11,760,553.48 in Q1 2020[22]